Apricot Capital

Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology.

Simcere Pharmaceutical Group is a prominent manufacturer and distributor of pharmaceuticals based in Nanjing, China, founded in 1995. The company has transitioned from a distributor to a leading player in China's pharmaceutical market, operating five GMP-certified manufacturing facilities and maintaining a strong workforce of over 4,000 employees. Simcere's product portfolio encompasses a wide range of medications targeting various therapeutic areas, including oncology, nervous system diseases, autoimmune disorders, and infections. Notable products include recombinant human endostatin injection for lung cancer, edaravone for acute cerebral infarction, and various formulations of amoxicillin for infections. The company also develops treatments for conditions such as arthritis, diarrhea, and cardiovascular diseases. Simcere has established strategic partnerships with organizations like Bristol-Myers Squibb and Jiangsu Alphamab Biopharmaceuticals to enhance its research and development capabilities.

Zhonghe Gene is a developer of gene technology focused on advancing life sciences research through innovative DNA biosynthesis technology. The company specializes in enzymatic DNA synthesis, offering tools such as an oligo biosynthesis instrument and a desktop Kb-level gene synthesizer. These technologies are designed to support biological laboratories in achieving significant breakthroughs in synthetic biology research, thereby promoting industrial advancements in the field.

Sinovent Inc. is a biopharmaceutical company established in 2016, with its headquarters in Suzhou, China, and additional offices in Beijing and Boston. The company focuses on developing innovative treatment methods through its advanced biotechnology platform and extensive management experience. Sinovent aims to address global healthcare challenges by combining expertise in science, management, and finance. Currently, it has 12 products in development, primarily targeting oncology, autoimmune diseases, and infectious diseases.

Yiteng Medical manufactures medical devices. The business's basic products are medical CT tubes and industrial CT microfocus X-ray tubes.

Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.

LinkZill is a high-tech company that specializes in the development and supply of organic semiconductor materials. Its primary offerings include organic semiconductor materials and thin-film transistor (TFT) arrays, which are applicable in various growing sectors such as biomedical electronics, healthcare, intelligent sports, and novel printed display technologies. The company also provides portable test systems, enhancing the functionality and application of its semiconductor products in diverse industries.

Axiata is a technological business that combines product creation, research, and sales of lab supplies. The company enables in vitro diagnostic reagent producers, pharmaceutical firms, and biological preparation businesses to build value by offering them effective services and products. The company continues to work in harmony with clients while providing goods that satisfy consumer demand. Customers can purchase products and OEM services from them.

Qihe Biotech is a manufacturer based in Zibo, China, specializing in the research and development, production, processing, sales, and export of edible fungi. The company serves a variety of international markets and offers technical guidance services to customers in different regions, ensuring a comprehensive approach to the distribution and utilization of its products.

Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.

PharmCube operates as a comprehensive big data service platform tailored for the pharmaceutical industry. It offers data management, media information, and consulting services, facilitating access to critical real-time data. The platform establishes systematic drug data standards and employs extensive data mining techniques to connect various aspects of drug research and development, clinical trials, registration, access, sales, and investment. By providing these services, PharmCube enables pharmaceutical companies to enhance their development planning and market positioning through informed decision-making based on reliable data insights.

Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Hepagene Therapeutics is focused on developing innovative treatments for liver diseases. The company engages in research and development efforts aimed at addressing conditions such as non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection, and liver cancer. By concentrating on these critical areas, Hepagene Therapeutics seeks to provide effective pharmaceutical solutions that can significantly improve patient outcomes in the realm of liver health.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of medical devices tailored for minimally invasive procedures. The company focuses on low-temperature plasma radio-frequency generators and electrodes, catering to sports medicine and tumor treatment. By leveraging domestic clinical data and technology from the United States, Forerunner Medical aims to meet both local and global healthcare needs. Their commitment to quality and safety is evident in their products, which are designed to offer enhanced performance, aesthetic appeal, and user convenience. With a strong emphasis on innovation and professional expertise, Forerunner Medical strives to provide superior medical technologies that improve surgical outcomes for doctors and patients alike.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. Utilizing high-throughput sequencing technology and intelligent algorithm analysis, GensKey addresses traditional challenges such as low detection rates, lengthy processes, and diagnostic accuracy. This innovative approach allows for timely and precise diagnoses for patients suffering from severe infections, ultimately improving patient outcomes by facilitating quicker access to appropriate medical interventions.

Shenqi Medical specializes in the research and manufacturing of innovative medical devices, primarily catering to the healthcare sector in China. The company offers a diverse range of products aimed at addressing cardiovascular issues, structural heart disease, and peripheral and neurovascular conditions. By focusing on minimally invasive surgical technologies, Shenqi Medical aims to enhance the safety and reliability of cardiovascular procedures, ultimately improving patient outcomes.

Jabrehoo focusing on clinical transformation and innovative research and development of related products in the field of assisted reproduction, genetics and eugenics, providing one-stop solutions for reproductive genetics for assisted reproduction couples, infertile patients, and people who are preparing for pregnancy, and promoting the localization of various detections.

Immvira, founded in Shenzhen, China, in May 2015 by a group of prominent professors from various universities, is focused on developing biopharmaceutical technology in the field of immunotherapy. The company specializes in creating oncolytic viruses and vector-type approaches aimed at treating cancer. Its primary product is a genetically engineered Oncolytic Herpes Simplex Virus, which is designed to target metastatic tumors or tumors that are difficult to access by direct injection. By leveraging this innovative technology, Immvira aims to provide more effective treatment solutions for patients suffering from cancer.

Shanghai MicroPort CardioFlow Medtech Co., Ltd., established in 2015, is a medical device company specializing in advanced minimally invasive therapies for structural heart diseases. As a subsidiary of MicroPort Scientific Corporation, it focuses on the research, development, and commercialization of innovative solutions for valvular heart diseases. The company's product portfolio includes VitaFlow, VitaFlow Liberty, Alwide Plus, and a range of transcatheter aortic valve implantation (TAVI), transcatheter mitral valve (TMV), and surgical valve products, along with procedural accessories. Primarily operating in China, MicroPort CardioFlow emphasizes the importance of improving patient quality of life through reliable and affordable healthcare solutions while maintaining a global vision for its products and services.

Yachuang Pharmaceuticals is an innovative pharmaceutical research and development company focusing on liver diseases such as NASH and HBV. Founder Dr. Xu has worked in multinational pharmaceutical companies such as Johnson & Johnson, with over 20 years of successful innovation and management of innovative drugs. experience.

SinoMab Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of therapeutic antibodies aimed at treating life-threatening immunological diseases. The company is particularly known for its flagship product, SM03 (Suciraslimab), which is positioned as a potential first-in-class monoclonal antibody for rheumatoid arthritis, with additional applications for diseases such as systemic lupus erythematosus and Sjogren's syndrome, as well as non-Hodgkin's lymphoma. SinoMab derives its revenue primarily from Hong Kong and is committed to advancing treatments for conditions that significantly impact patients' lives.

Tavotek Biotherapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with severe diseases that lack effective treatments. The company is led by experienced pharmaceutical executives who have successfully developed numerous biologics currently on the market. Tavotek employs three distinct research and development platforms: TavoSelect, an innovative Phage Display Library; TavoPrecise, an engineering platform for tissue-specific biologics; and TavoMIP, a multicyclic peptide platform. This diverse array of technologies supports Tavotek's extensive pipeline of product candidates, which targets cancers, autoimmune disorders, and infectious diseases, thereby addressing significant unmet medical needs in the healthcare landscape.

Jiuxin Medical is a medical company that provides pre-hospital first-aid products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the products developed have complete independent intellectual property rights.

Bellen Chemistry is a premier provider of a variety of heterocycles. Our activity is focused on the design and development of novel molecules,6361413375267061158256368.jpgintermediates for the Chemical and Pharmaceutical industries. Bellen Chemistryhas a strong R&D team with a talent pool of 200+ trained scientists. We have excellent track records, as we deliver unrivalled chemical innovation to our customers worldwide.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.